New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novartis AG

NVS

Healthcare Drug Manufacturers General

Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.

Revenue
+4.67%
EPS
−68.8%
Free cash flow
−17.8%
Total debt
+53.9%

Quarter to September 2026, against a year earlier

151.63 0.42 +0.28%
Market cap
$277.7B
P/E
28.8×
Fwd P/E FY26e
24.0×
Dividend yield
3.13%
F-score
8/9
ROIC
12.1%
Net debt / EBITDA
1.0×
Payout ratio
0.9×

Where the cash went Twelve months to Sep 30, 2026

Free cash flow of $15.7B covered $15.3B of dividends and buybacks. Cash fell by $686.0M. Lines the picture does not name came to −$5.4B. What is a cash flow statement?

Free cash flow
$15.7B 90.6% of operating cash flow
Returned to shareholders
$15.3B 97.5% of free cash flow
Debt, net
$16.2B borrowed
Change in cash
−$686.0M over the period
Where the cash went, in billions of dollars
Operating cash flow17.3
Capital expenditures−1.6
Free cash flow15.7
Acquisitions, net−12.7
From investments, net+0.9
Dividends−9.1
Buybacks, net−6.2
Debt raised, net+16.2
Other−5.4
Change in cash−0.7
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Operating cash flow$19.1B$19.2B$18.4B$17.3B
Capex−$1.5B−$1.6B−$1.6B−$1.6B
Free cash flow$17.6B$17.5B$16.8B$15.7B

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Net Income

+8 more TTM periods

13,967.00 13,514.00 12,747.00 10,013.00
Depreciation & Amortization
5,275.00 5,288.00 5,442.00 7,693.00
Non Cash Items (Other)
2,962.00 2,482.00 2,495.00 3,205.00
Accounts Receivable Change
(1,124.00) (585.00) (674.00) (1,024.00)
Change in inventories
34.00 (116.00) (42.00) 118.00
Accounts Payable Change
(273.00) (154.00) (195.00) (94.00)
Change in other assets and liabilities
(214.00) 259.00 105.00 (1,197.00)
Other operating activities
(1,483.00) (1,513.00) (1,485.00) (1,496.00)
Operating Cash Flow
19,144.00 19,175.00 18,393.00 17,325.00
Capital expenditures
(1,535.00) (1,632.00) (1,597.00) (1,636.00)
Change in intangibles (net)
(2,188.00) (1,415.00) (1,619.00) (1,544.00)
Net Aquisitions
(235.00) (12,274.00) (11,737.00) (12,741.00)
Short Term Investments Change (Net)
1,781.00 1,066.00 769.00 814.00
Long-Term Investments Change (Net)
93.00 105.00 134.00 76.00
Other investing activities
(2,793.00) (2,793.00) (3,755.00) (3,660.00)
Investing cash flow
(4,877.00) (16,943.00) (17,805.00) (18,691.00)
Repayment/Issuance of Debt (Net)
2,430.00 14,526.00 16,448.00 16,191.00
Equity Repurchase (Common, Net)
(9,185.00) (8,345.00) (6,836.00) (6,234.00)
Dividends Paid (Total)
(7,818.00) (8,682.00) (9,068.00) (9,068.00)
Other financial activities
(294.00) (239.00) (91.00) (111.00)
Financing cash flow
(14,867.00) (2,740.00) 453.00 778.00
Exchange Rate Adjustment
576.00 319.00 (81.00) (98.00)
Change in Cash
(24.00) (189.00) 960.00 (686.00)
Beginning Cash
11,459.00 11,435.00 11,435.00 11,435.00
Ending Cash
11,435.00 11,246.00 12,395.00 10,749.00
Stock Based Compensation
1,096.00 1,137.00 1,137.00 1,136.00
Dividends Paid (Common)
(7,818.00) (8,682.00) (9,068.00) (9,068.00)
Assets Liabilities Change (Total)
(1,577.00) (596.00) (806.00) (2,090.00)
Investments Change (Net)
1,874.00 1,171.00 903.00 890.00
Issuance/Purchase of Shares
(9,185.00) (8,345.00) (6,836.00) (6,234.00)

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026